Pucotenlimab Combined with Lenvatinib

Phase 2Small molecule

Pucotenlimab Combined with Lenvatinib is one of 81 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 1

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

363 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

31 2

Votrient

Novartis

Phase 3

25 3

Nexavar

Bayer

Phase 3

23 4

Lenvima

Eisai

Phase 3

21 5

Inlyta

PPrism Pharmaceuticals

Phase 3

27 6

Tecentriq

Roche

Phase 3

8 7

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

18 8

Imjudo

AstraZeneca

Phase 3

3 9

Imfinzi

AstraZeneca

Phase 3

2 10

Depo-Provera

Eli Lilly

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gastroesophageal Junction Adenocarcinoma1 trial

Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Enrolling by invitation·FFujian Medical University·Phase 1·NCT07356466·100 enrolled

Renal Cell Carcinoma1 trial

Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT06129955·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pucotenlimab Combined with Lenvatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pucotenlimab Combined with Lenvatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pucotenlimab Combined with Lenvatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Pucotenlimab Combined with Lenvatinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gastroesophageal Junction Adenocarcinoma1 trial

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News